공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

정신의학 관련 각종 제휴 계약 : 계약 조건 및 합의 내용

Global Psychiatry Partnering 2014-2021: Deal trends, players and financials

리서치사 Current Partnering, a division of Wildwood Ventures Limited
발행일 2021년 03월 상품 코드 238157
페이지 정보 영문 550+ Pages
가격
US $ 3,495 ₩ 3,938,000 PDF (Single User License)
US $ 5,245 ₩ 5,910,000 PDF (Multi User License - 2 to 5 Users)
US $ 10,495 ₩ 11,825,000 PDF (Single Site License - 6+ Users)
US $ 17,495 ₩ 19,713,000 PDF (Global License)


정신의학 관련 각종 제휴 계약 : 계약 조건 및 합의 내용 Global Psychiatry Partnering 2014-2021: Deal trends, players and financials
발행일 : 2021년 03월 페이지 정보 : 영문 550+ Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

정신의학 관련 각종 제휴 계약에 대해 조사분석했으며, 최근의 각종 계약 동향, 대형 계약 및 대형 의약품 사업체의 계약 개요, 계약 부문·개발 단계·기술 부문·적응증 부문별 디렉토리 등을 정리하여 전해드립니다.

개요

제1장 서론

제2장 정신의학 관련 각종 계약의 동향

  • 서론
  • 과거 수년간의 정신의학 관련 제휴
  • 대형 제약회사의 계약 활동
  • 정신의학 관련 사업에 적극적이지 않은 대형 제약회사
  • 정신의학 관련 제휴 : 계약 유형별
  • 정신의학 관련 제휴 : 산업 부문별
  • 정신의학 관련 제휴 : 개발 단계별
  • 정신의학 관련 제휴 : 기술 유형별
  • 평균 계약기간
  • 선불금
  • 목표 달성 보수
  • 로열티 요율 등

제3장 주요 계약

  • 서론
  • 주요 계약 : 거래액별
  • 대형 제약회사와 관련된 주요 계약

제4장 대형 제약회사의 계약

  • 기업 개요

제5장 계약 디렉토리

  • 서론
  • 기업별 : A-Z
  • 계약 유형별
    • 자산 구입
    • 대기업의 아웃라이선싱
    • 공동 개발
    • 공동 R&D
    • 서비스 계약
    • 공동 프로모션
    • CRADA
    • 개발
    • 유통 판매
    • 평가
    • 양도
    • 조인트 벤처
    • 라이선싱
    • 제조
    • 마케팅
    • 재료 전달
    • 옵션
    • 프로모션
    • 연구
    • 화해 관련
    • 스핀아웃
    • 공급
    • 기술 이전
  • 개발 단계별
    • Drug Discovery
    • 전임상
    • 단계 I
    • 단계 II
    • 단계 III
    • 신청 등록
    • 시판
  • 기술 유형별
    • 보조제
    • 해석
    • 동물 모델
    • 어세이
    • 바이오 디펜스
    • 바이오인포매틱스
    • 생물학적 화합물
    • 바이오마커
    • 바이오소재
    • 바이오프로세싱
    • 바이오시밀러/바이오베터
    • 혈액제재
    • 세포 배양
    • 세포 치료
    • 임상검사
    • 진단(동반)
    • 디바이스
    • 진단
    • Drug Discovery 툴
    • DNA 프로브
    • 약물전달
    • 실현 기술
    • 에피제네틱스
    • 기기
    • 설비
    • 유전자 치료
    • 게노믹스
    • 글리코믹스
    • 이미징
    • 임플란트
    • 인비트로 모델
    • 마이크로어레이
    • 모노클로널 항체 테크놀러지 등
  • 적응증별
    • 정신병
    • 불안장애
    • 전반성 불안장애
    • 패닉장애
    • PTSD
    • 주의력결핍 과잉행동장애(ADHD)
    • 조울증
    • 만성피로증후군
    • 인지장애
    • 치매
    • 알츠하이머
    • 루이소체 치매
    • 자폐증
    • 조증
    • 강박성 장애
    • 정신분열증
    • 수면증애

제6장 제휴 기회

  • 온라인 파트너링
  • 파트너링 이벤트
  • 관련 자료

부록

도표

KSA 12.05.09

The Global Psychiatry Partnering 2014-2021: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the psychiatry partnering deals and agreements entered into by the worlds leading healthcare companies

Global Psychiatry Partnering 2014 to 2021 provides the full collection of Psychiatry disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Trends in Psychiatry partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Psychiatry partnering agreement structure

Psychiatry partnering contract documents

Top Psychiatry deals by value

Most active Psychiatry dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Psychiatry deals.

The report presents financial deal terms values for Psychiatry deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Psychiatry dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Psychiatry dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Psychiatry deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Psychiatry dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Psychiatry deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Psychiatry partnering deals by specific Psychiatry target announced since 2014. The chapter is organized by specific Psychiatry therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Psychiatry partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Psychiatry partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Psychiatry technologies and products.

Report scope

Global Psychiatry Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Psychiatry trends and structure of deals entered into by leading companies worldwide.

Global Psychiatry Partnering 2014 to 2021 includes:

  • Trends in Psychiatry dealmaking in the biopharma industry since 2014
  • Analysis of Psychiatry deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Psychiatry deal contract documents
  • Comprehensive access to over 780 Psychiatry deal records
  • The leading Psychiatry deals by value since 2014
  • Most active Psychiatry dealmakers since 2014
  • The report includes deals for the following indications: Akathisia, Anxiety disorder, Generalised anxiety disorder, Panic disorder, Post traumatic stress disorder, Attention deficit hyperactivity disorder, Bipolar disorder, Chronic fatigue syndrome, Cognitive impairment, Delirium, Dementia, Alzheimers, Dementia with lewy bodies, Vascular dementia, Depression, Dystonia, Eating disorder, Anorexia, Bulimia, Learning disability, Aspergers, Autism, Mania, Obsessive compulsive disorder, Personality disorder, Schizophrenia, Sleep disorders, Insomnia, Narcolepsy, Sleep apnoea, Tardive dyskinesia, Tourettes, plus other psychiatric indications.

In Global Psychiatry Partnering 2014 to 2021, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Psychiatry Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 780 psychiatry deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Psychiatry Partnering 2014 to 2021 provides the reader with the following key benefits:

  • In-depth understanding of Psychiatry deal trends since 2014
  • Access Psychiatry deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Psychiatry partner companies
  • Comprehensive access to over 780 links to actual Psychiatry deals entered into by the world's biopharma companies
  • Indepth review of Psychiatry deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Psychiatry opportunities
  • Uncover companies actively partnering Psychiatry opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Psychiatry dealmaking

  • 2.1. Introduction
  • 2.2. Psychiatry partnering over the years
  • 2.3. Psychiatry partnering by deal type
  • 2.4. Psychiatry partnering by industry sector
  • 2.5. Psychiatry partnering by stage of development
  • 2.6. Psychiatry partnering by technology type
  • 2.7. Psychiatry partnering by therapeutic indication

Chapter 3 -Financial deal terms for Psychiatry partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Psychiatry partnering
  • 3.3. Psychiatry partnering headline values
  • 3.4. Psychiatry deal upfront payments
  • 3.5. Psychiatry deal milestone payments
  • 3.6. Psychiatry royalty rates

Chapter 4 - Leading Psychiatry deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Psychiatry partnering
  • 4.3. List of most active dealmakers in Psychiatry
  • 4.4. Top Psychiatry deals by value

Chapter 5 - Psychiatry contract document directory

  • 5.1. Introduction
  • 5.2. Psychiatry partnering deals where contract document available

Chapter 6 - Psychiatry dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Psychiatry therapeutic target

Appendices

  • Appendix 1 - Directory of Psychiatry deals by company A-Z 2014 to 2021
  • Appendix 2 - Directory of Psychiatry deals by deal type 2014 to 2021
  • Appendix 3 - Directory of Psychiatry deals by stage of development 2014 to 2021
  • Appendix 4 - Directory of Psychiatry deals by technology type 2014 to 2021
  • Further reading on dealmaking
  • Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering
  • Table of figures
  • Figure 1: Psychiatry partnering since 2014
  • Figure 2: Psychiatry partnering by deal type since 2014
  • Figure 3: Psychiatry partnering by industry sector since 2014
  • Figure 4: Psychiatry partnering by stage of development since 2014
  • Figure 5: Psychiatry partnering by technology type since 2014
  • Figure 6: Psychiatry partnering by indication since 2014
  • Figure 7: Psychiatry deals with a headline value
  • Figure 8: Psychiatry deals with upfront payment values
  • Figure 9: Psychiatry deals with milestone payment
  • Figure 10: Psychiatry deals with royalty rates
  • Figure 11: Active Psychiatry dealmaking activity- 2014 to 2021
  • Figure 12: Top Psychiatry deals by value since 2014
Back to Top
전화 문의
F A Q